German pharma benefiting from a Brexit boost?

24 Oct 2019

Germany establishes itself as Europe's leading pharma market in 2019.

Research conducted by CPhI Worldwide ranks Germany as Europe’s preeminent pharma industry. The data was drawn from the CPhI Annual Report and includes opinions from more than 350 international pharma companies.

German pharma benefiting from a Brexit boost?

The ‘CPhI Pharma Index’ is the only annually produced perception ranking of the world’s top performing countries. It provides vital insights into the world’s leading pharma economies across all attributes, and indicates which markets have the greatest business prospects and growth potential.

The results see Germany consolidate its status as an elite pharmaceutical market, finishing ahead of its European rivals in API manufacturing, competitiveness, innovation, finished product manufacturing, and growth potential.

CPhI Worldwide, which brings every stage of the pharmaceutical supply chain together – from ingredients and finished formulations to machinery, packaging, outsourcing and biopharmaceuticals – is widely used as a barometer of pharma’s overall strength and growth potential. This year, the event is expected to welcome over 45,000 attendees and 2,500 exhibitors, with nearly all major pharma countries registering a positive outlook for 2019 and 2020. Significantly, the outlook for Germany amongst both its domestic and international executives is particularly strong – improving its score across all metrics since 2018.

One particularly notable trend is the sudden rise in anticipated growth potential for Germany in 2019/2020, increasing by 11% from 2018. The research’s authors attribute the shifting European outlook over the last couple of years to wider macro changes, as well as the continued strength of European pharma. Germany is perceived to be reaping a ‘Brexit boost’ in its medium-term growth potential – with an equal drop in the UK scores directly correlating to the increases seen in Germany’s.

“It is no surprise that Germany has again emerged as a global pharmaceutical leader. However, the country has further increased its score, suggesting it has consolidated its position as Europe’s top pharma industry. There are a number of leading German manufacturers and service providers in the pharmaceutical industry in attendance at CPhI Worldwide this year, including BASF, B. Braun, Evonik, Vetter Pharma, AG, Wacker, Corden Pharma and Merck. In total, 223 German companies will be showcasing their strength to a global audience, with executives attending from over 150 countries, ” said Orhan Caglayan, Brand Director at CPhI Worldwide.

The full CPhI Pharma Market Index will be made available later in the year within its 2019 Annual Industry Report.

Caglayan, added: “Significantly, in the event’s return to Frankfurt, the pharma industry in Germany is perceived as an international industry pioneer according to the latest CPhI Pharma Index. The country has the highest score in ‘API manufacturing quality’ globally, as well as the leading scores in Europe for ‘competitiveness’, ‘innovation’ and ‘finished product manufacturing’. Collectively, this points to extremely strong prospects for the German pharma industry in 2020.”

Read More

Related news

Europe predicted to surpass the US in biologic manufacturing capacity by 2023

Europe predicted to surpass the US in biologic manufacturing capacity by 2023

6 Nov 2019

Demand for biological manufacturing is growing faster than capacity growth.

Read more 
China on course for 'massive' bio capacity shortfall

China on course for 'massive' bio capacity shortfall

4 Nov 2019

A shortage of qualified personnel may be a drag factor in cell and gene therapies; in China 100,00L of capacity will need to be added every year to meet bio demand.

Read more 
The talk of the show?

The talk of the show?

23 Oct 2019

Outsourcing, biologics, generics and patient compliance look set to get tongues wagging at this year's CPhI WW.

Read more 
‘FDA should withdraw ANDAs’ says expert

‘FDA should withdraw ANDAs’ says expert

21 Oct 2019

CPhI Worldwide's Annual Report suggests repeat offenders of regulatory infringements should be barred from importing into the US.

Read more 
Cytel to hold Complex Innovative Trial Design Symposium

Cytel to hold Complex Innovative Trial Design Symposium

18 Oct 2019

Experts to discuss innovative solutions to rare disease clinical trials.

Read more 
Finalists announced for this year's CPhI Worldwide Awards

Finalists announced for this year's CPhI Worldwide Awards

17 Oct 2019

The winners’ shortlist is packed with 40 of the industry’s most innovative companies and individuals who are shaping the future of pharma.

Read more 
One-stop-platform for plant-based nutraceuticals

One-stop-platform for plant-based nutraceuticals

2 Oct 2019

In 2020, nutra brands will look to ensure they have plant-based options across all product classes with many actively looking to move entire portfolios plant-based.

Read more 
Industry on the brink of a new age of smart pharma manufacturing

Industry on the brink of a new age of smart pharma manufacturing

27 Sep 2019

Report predicts tomorrow’s biggest industry winners will need to invest now ahead of the curve.

Read more 
Huge boom in Korean Pharma reported at CPhI Korea

Huge boom in Korean Pharma reported at CPhI Korea

20 Sep 2019

Event sees new Memorandum of Understanding signed by PROLMED and KPTA.

Read more 
Drivers behind Saudi Arabia’s forecast 10.74 $billion 2022 market

Drivers behind Saudi Arabia’s forecast 10.74 $billion 2022 market

9 Sep 2019

Growing population, increase in non-communicable diseases and major investment in new hospitals, clinics and treatments driving growth.

Read more